Literature DB >> 30328549

Compound GDC, an Isocoumarin Glycoside, Protects against LPS-Induced Inflammation and Potential Mechanisms In Vitro.

Yuqin Zhang1,2,3, Guohong Yan4, Chengtao Sun1,3, Lihong Nan1,3, Xiaoying Wang1,3, Wei Xu5,6, Kedan Chu7,8.   

Abstract

Compound 3R-(4'-hydroxyl-3'-O-β-D-glucopyranosyl phenyl)-dihydro isocoumarin (GDC) is a natural isocoumarin, recently isolated from the stems of H. paniculiflorum. However, we know little about the effects of GDC on rheumatoid arthritis (RA). This study aims to investigate the protective effects and potential mechanisms of GDC against LPS-induced inflammation in vitro. Fibroblast-like synoviocytes (FLSs) obtained from synovial tissue of rats were induced by lipopolysaccharide (LPS) and treated with GDC. Cell viability was determined by mitochondrial-respiration-dependent3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. Secretion of various inflammatory mediators was analyzed by ELISA and RayBio® Rat Cytokine Antibody Array. Potential mechanisms that are associated with anti-inflammatory effect were examined by Western blot. Results showed that GDC significantly inhibited the production of tumor necrosis factor alpha (TNF-α) and interleukin- (IL-) 6 induced by LPS. GDC also reduced the expression of inducible nitric oxide synthase (iNOS), TNF-α, IL-6, and IL-1β, as well as proinflammatory cytokines such as activin A, ciliary neurotrophic factor (CNTF), fractalkine, IFN-γ, IL-4, and TIMP-1. Moreover, GDC inhibited LPS-induced phosphorylation of extracellular regulated protein kinases (ERK1/2), p38 mitogen-activated protein kinases (p38), c-Jun N-terminal kinase (JNK), and IκB. And GDC also blocked NF-κBp65 nuclear translocation. All the results suggested that the protective effects of GDC against LPS-induced inflammation in vitro may be related with NF-κB and JNK signaling pathway.

Entities:  

Keywords:  MAPK signaling pathway; NF-κB signaling pathway; fibroblast-like synoviocyte; inflammation; isocoumarin; rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 30328549     DOI: 10.1007/s10753-018-0908-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  25 in total

Review 1.  Cytokine pathways and joint inflammation in rheumatoid arthritis.

Authors:  E H Choy; G S Panayi
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

Review 2.  Side effects and management of side effects of methotrexate in rheumatoid arthritis.

Authors:  K Albrecht; U Müller-Ladner
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

Review 3.  Rheumatoid arthritis progression mediated by activated synovial fibroblasts.

Authors:  Elena Neumann; Stephanie Lefèvre; Birgit Zimmermann; Steffen Gay; Ulf Müller-Ladner
Journal:  Trends Mol Med       Date:  2010-08-24       Impact factor: 11.951

Review 4.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

Review 5.  Evidence that cytokines play a role in rheumatoid arthritis.

Authors:  Fionula M Brennan; Iain B McInnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

6.  p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6.

Authors:  Bernat Baeza-Raja; Pura Muñoz-Cánoves
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

Review 7.  The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis.

Authors:  Erika H Noss; Michael B Brenner
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 8.  Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.

Authors:  Sonja Herman; Gerhard Krönke; Georg Schett
Journal:  Trends Mol Med       Date:  2008-05-09       Impact factor: 11.951

Review 9.  Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.

Authors:  Jalal A Jazayeri; Graeme J Carroll; Ann B Vernallis
Journal:  Int Immunopharmacol       Date:  2009-10-03       Impact factor: 4.932

Review 10.  Cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.